Senseonics Launches the “Ever Mobile Clinic”
Post# of 51
June 25, 2018
ORLANDO--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) today announced the launch of the company’s Ever Mobile Clinic Tour, a program to bring hands-on diabetes device training and education directly to U.S. patients and healthcare professionals in their local areas via a custom-built 18-wheeler mobile training facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005634/en/
Ever Mobile Clinic (Photo: Business Wire)
Ever Mobile Clinic (Photo: Business Wire)
The national education-based tour features the Ever Mobile Clinic, a mobile educational facility custom-built within a semi-truck to accommodate the education and training of healthcare professionals and patients in the use of the company’s recently approved Eversense® Continuous Glucose Monitoring (CGM) System. The Ever Mobile Clinic was previewed last week at the American Diabetes Association, and in July, Senseonics will kick off the mobile clinic’s national tour bringing education and training to major markets across the United States.
The modern multifunctional Ever Mobile Clinic houses a video theatre, two hands-on demonstration stations and procedure room. The mobile clinic delivers hands-on immersive product demonstration and hands-on training directly to local healthcare professionals and patients in cities across the country.
“The mobile clinic is an innovative forum to deliver physician and patient education on the merits of CGM, including potentially modules in using data to optimize individual therapeutic outcomes,” says Richard Bergenstal, MD, Executive Director at the International Diabetes Center. “A traveling semi-truck outfitted with the right tools and program is a new way to bring these educational opportunities to local communities.”
The Ever Mobile Clinic Tour will visit conferences, health care groups, health care systems and community events, and is staffed with qualified trainers who offer product and sensor procedure training and relevant information on diabetes and glucose monitoring.
Senseonics’ application to market the Eversense® CGM System for use by people with diabetes was approved by the U.S. Food and Drug Administration on June 21, 2018. The Eversense System is the first and only CGM system to feature an implantable glucose sensor and provide long-term continuous monitoring for up to three months.
“We believe the Eversense System offers unique features that will help open up CGM to millions of people with diabetes who currently are not taking advantage of its benefits,” said Tim Goodnow, President and CEO of Senseonics. “And just as important as it is to bring to market innovative device technology that better fits patients’ lives, it's equally important that we’re innovative about how we bring training in the use of the product to patients and their physicians. It has to fit their work and personal lives, and so this is just a new and additional option for training and education to supplement our in-office, online and other training efforts.”